Markets

Cellectis S.A. (CLLS) Jumps: Stock Adds 7.6% in Session

Cellectis S.A.CLLS was a big mover last session, as its shares rose roughly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Yesterday's rally reverses the recent downtrend for the company, as the stock is now down roughly 24% in the past one-month time frame.

Over the last 30 days, the company did not witness any estimate revision while the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.

Cellectis currently has a Zacks Rank #2 (Buy).

Another favorably ranked biomedical stock is Amgen Inc. AMGN with a Zacks Rank #1 (Strong Buy).

Is CLLS going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMGEN INC (AMGN): Free Stock Analysis Report

CELLECTIS-ADR (CLLS): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CLLS AMGN

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More